Magnetic Fields / TumCCA Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱
Features: Therapy
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Reactive oxygen species (ROS) ↑ ROS (P→R); often sustained (G) ↑ ROS (P); ↔/↓ net ROS (R→G) P, R, G Upstream redox perturbation MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2 NRF2 antioxidant response ↔ / insufficient NRF2 induction (R→G) ↑ NRF2 activation (R→G) R, G Adaptive redox defense Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3 Glutathione (GSH) homeostasis ↓ GSH (R→G) ↔ or transient ↓ (R) with recovery (G) R, G Redox buffering capacity GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4 Superoxide dismutase (SOD) / antioxidant enzymes ↔ or inadequate enzyme upshift (G) ↑ SOD/GPx/CAT capacity (G) G Longer-term antioxidant remodeling Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak (P→R) ↔ mild, reversible ETC perturbation (P→R) P, R Bioenergetic destabilization ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6 Mitochondrial membrane potential (ΔΨm / MMP) ↓ ΔΨm (R); may progress (G) ↔ preserved or reversible dip (R) R, G Mitochondrial dysfunction thresholding ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7 Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux) ↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G) ↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G) P, R, G Stress signal amplification Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8 Mitochondrial permeability transition pore (MPTP) ↑ MPTP opening propensity (R); sustained opening possible (G) ↔ transient or closed (R→G) P, R, G Commitment point for mitochondrial failure MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9 ER stress / UPR ↑ ER stress (R); CHOP-commitment possible (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis stress Often downstream of ROS + Ca²⁺ handling perturbations
10 DNA damage (oxidative) ↑ damage markers (R→G) ↔ or repaired (G) R, G Checkpoint pressure Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11 LDH / glycolytic flux ↓ glycolytic performance (R→G) ↔ flexible substrate switching (R→G) R, G Metabolic vulnerability Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12 Thioredoxin system (Trx / TrxR) ↓ functional reserve / overload (R→G) ↔ preserved capacity (G) R, G Parallel antioxidant system stress Useful when GSH-only does not explain redox phenotype
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.


TumCCA, Tumor cell cycle arrest: Click to Expand ⟱
Source:
Type:
Tumor cell cycle arrest refers to the process by which cancer cells stop progressing through the cell cycle, which is the series of phases that a cell goes through to divide and replicate. This arrest can occur at various checkpoints in the cell cycle, including the G1, S, G2, and M phases. S, G1, G2, and M are the four phases of mitosis.


Scientific Papers found: Click to Expand⟱
356- AgNPs,  MF,    Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study
- in-vitro, BC, MCF-7 - in-vitro, Bladder, HTB-22
Apoptosis↑, P53↑, iNOS↑, NF-kB↑, Bcl-2↓, ROS↑, SOD↑, TumCCA↑, eff↑, Catalase↑, other↑,
524- MF,    Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs)
- vitro+vivo, PC, MS-1 - vitro+vivo, PC, HUVECs
other↓, TumCP↓, TumCMig↓, VEGFR2↓, TumVol↓, HSP70/HSPA5↓, HSP90↓, TumCCA↑, angioG↓,
3464- MF,    Progressive Study on the Non-thermal Effects of Magnetic Field Therapy in Oncology
- Review, Var, NA
AntiTum↑, TumCG↓, TumCCA↑, Apoptosis↑, TumAuto↑, Diff↑, angioG↓, TumMeta↓, EPR↑, ChemoSen↑, ROS↑, DNAdam↑, P53↑, Akt↓, MAPK↑, Casp9↑, VEGFR2↓, P-gp↓,
497- MF,    In Vitro and in Vivo Study of the Effect of Osteogenic Pulsed Electromagnetic Fields on Breast and Lung Cancer Cells
- vitro+vivo, NA, MCF-7 - vitro+vivo, NA, A549
TumCG↓, TumVol↓, Casp3↑, Casp7↑, Apoptosis↑, DNAdam↑, TumCCA↑, ChemoSen↑, EPR↑,
496- MF,    Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, ZR-75-1 - in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231
ROS↑, PI3K↓, Akt↓, GSK‐3β↑, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, CycB/CCNB1↓, TumCCA↑, p‑Akt↓, TumCP↓, selectivity↑, eff↓,
487- MF,    Extremely Low-Frequency Electromagnetic Fields Cause G1 Phase Arrest through the Activation of the ATM-Chk2-p21 Pathway
- in-vitro, NMSC, HaCaT
ATM↑, Chk2↑, P21↑, TumCCA↑,
508- MF,  doxoR,    Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line
- in-vitro, BC, MCF-7
ROS↑, Apoptosis↑, TumCCA↑,
4353- MF,  Chemo,    Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells
- in-vitro, BC, MCF-7
TumCCA↑, Apoptosis↑, eff↑, TumCCA↑, Casp↝, p‑CDK2↓, cycE/CCNE↓, Fas↑, BAX↑, survivin↓, Mcl-1↓, cl‑PARP↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑,
3477- MF,    Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis
- Review, NA, NA
*Ca+2↑, *VEGF↑, *angioG↑, Ca+2↑, ROS↑, Necroptosis↑, TumCCA↑, Apoptosis↑, *ATP↑, *FAK↑, *Wnt↑, *β-catenin/ZEB1↑, *ROS↑, p38↑, MAPK↑, β-catenin/ZEB1↓, CSCs↓, TumCP↓, ROS↑, RadioS↑, Ca+2↑, eff↓, NO↑,
200- MFrot,  MF,    Moderate intensity low frequency rotating magnetic field inhibits breast cancer growth in mice
- in-vivo, BC, MDA-MB-231 - in-vivo, BC, MCF-7
ALAT↓, TumVol↓, TumCCA↑, TumCG↓, TumMeta↓, Imm↑, P53↑, ALAT↓, AST↓,
198- MFrot,  MF,    Biological effects of rotating magnetic field: A review from 1969 to 2021
- Review, Var, NA
AntiCan↑, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, TumMeta↓, TumCCA↑, ETC↓, MMP↓, TumCD↑, selectivity↑, ROS↑, Casp3↑, TumCG↓, TumCCA↑, ChrMod↑, TumMeta↓, Imm↑, DCells↑, Akt↓, OS⇅, toxicity↓, QoL↑, hepatoP↑, Pain↓, Weight↑, Strength↑, Sleep↑, IL6↓, CD4+↑, CD8+↑, Ca+2↑, radioP↑, chemoP↑, *BMD↑, *AntiAge↑, *AMPK↑, *P21↓, *P53↓, *mTOR↓, *OS↑, *β-Endo↑, *5HT↓,
220- MFrot,  MF,    Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation
- in-vitro, Melanoma, B16-F10
OS↑, DCells↑, T-Cell↑, Apoptosis↑, IL1↑, IFN-γ↓, IL10↑, TumCG↓, ROS↑, TumCP↓, TumCCA↑, ChrMod↑, CXCL9↓, CXCL12↓, CD4+↑, CD8+↑,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

Catalase↑, 1,   ROS↑, 8,   SOD↑, 1,  

Mitochondria & Bioenergetics

ETC↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis

ALAT↓, 2,  

Cell Death

Akt↓, 3,   p‑Akt↓, 1,   Apoptosis↑, 8,   BAX↑, 2,   Bcl-2↓, 2,   Casp↝, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp7↑, 1,   cl‑Casp7↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Chk2↑, 1,   Fas↑, 1,   iNOS↑, 1,   MAPK↑, 2,   Mcl-1↓, 1,   Necroptosis↑, 1,   p38↑, 1,   survivin↓, 1,   TumCD↑, 1,  

Transcription & Epigenetics

BowelM↑, 1,   ChrMod↑, 2,   other↓, 1,   other↑, 1,  

Protein Folding & ER Stress

HSP70/HSPA5↓, 1,   HSP90↓, 1,  

Autophagy & Lysosomes

TumAuto↑, 1,  

DNA Damage & Repair

ATM↑, 1,   DNAdam↑, 2,   P53↑, 3,   cl‑PARP↑, 2,  

Cell Cycle & Senescence

p‑CDK2↓, 1,   CycB/CCNB1↓, 1,   cycE/CCNE↓, 1,   P21↑, 1,   TumCCA↑, 14,  

Proliferation, Differentiation & Cell State

CSCs↓, 1,   Diff↑, 1,   GSK‐3β↑, 1,   PI3K↓, 1,   TumCG↓, 5,  

Migration

Ca+2↑, 3,   CXCL12↓, 1,   TumCMig↓, 1,   TumCP↓, 4,   TumMeta↓, 4,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature

angioG↓, 2,   EPR↑, 2,   NO↑, 1,   VEGFR2↓, 2,  

Barriers & Transport

P-gp↓, 1,  

Immune & Inflammatory Signaling

CD4+↑, 2,   CXCL9↓, 1,   DCells↑, 2,   IFN-γ↓, 1,   IL1↑, 1,   IL10↑, 1,   IL6↓, 1,   Imm↑, 2,   NF-kB↑, 1,   T-Cell↑, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 2,   eff↓, 2,   eff↑, 2,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers

ALAT↓, 2,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes

AntiCan↑, 1,   AntiTum↑, 1,   Appetite↑, 1,   breath↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   OS↑, 1,   OS⇅, 1,   Pain↓, 2,   QoL↑, 1,   radioP↑, 1,   Sleep↑, 1,   Strength↑, 2,   toxicity↓, 1,   TumVol↓, 3,   Weight↑, 1,  

Infection & Microbiome

CD8+↑, 2,  
Total Targets: 95

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

ROS↑, 1,  

Mitochondria & Bioenergetics

ATP↑, 1,  

Core Metabolism/Glycolysis

AMPK↑, 1,  

DNA Damage & Repair

P53↓, 1,  

Cell Cycle & Senescence

P21↓, 1,  

Proliferation, Differentiation & Cell State

mTOR↓, 1,   Wnt↑, 1,  

Migration

Ca+2↑, 1,   FAK↑, 1,   β-catenin/ZEB1↑, 1,   β-Endo↑, 1,  

Angiogenesis & Vasculature

angioG↑, 1,   VEGF↑, 1,  

Synaptic & Neurotransmission

5HT↓, 1,  

Clinical Biomarkers

BMD↑, 1,  

Functional Outcomes

AntiAge↑, 1,   OS↑, 1,  
Total Targets: 17

Scientific Paper Hit Count for: TumCCA, Tumor cell cycle arrest
12 Magnetic Fields
3 Magnetic Field Rotating
1 Silver-NanoParticles
1 doxorubicin
1 Chemotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:322  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page